Literature DB >> 18556772

Confirmation of single exon deletions in MLH1 and MSH2 using quantitative polymerase chain reaction.

Cecily P Vaughn1, Elaine Lyon, Wade S Samowitz.   

Abstract

Deletions of one or more exons in the mismatch repair genes MLH1 and MSH2 have been implicated in a significant fraction of hereditary nonpolyposis colorectal cancer (HNPCC or Lynch syndrome). Multiplex ligation-dependent probe amplification (MLPA) detection of deletions of multiple sequential exons is widely accepted; however, there is concern over the reliability of MLPA results showing single exon deletions. Given the clinical implications of a diagnosis of Lynch syndrome, it is important to use an alternative technique to confirm single exon deletions. To verify single exon deletions, we developed a SYBR Green-based quantitative polymerase chain reaction (PCR) assay. Clinical DNA samples containing deletions in 33 of the 35 exons in MLH1 and MSH2, previously screened by MLPA, were evaluated by quantitative PCR. Gene dosage ratios were determined by both the relative standard curve method and by the 2(-DeltaDeltaC(T)) method. Deleted exons had gene dosage ratios of 0.4 to 0.6, while nondeleted exons exhibited ratios of 0.8-1.3. We found 100% concordance between the quantitative PCR and MLPA results, including confirmation of all single exon deletions. The 2(-DeltaDeltaC(T)) method was as accurate as using standard curves for the calculation of ratios. Single exon deletions in MLH1 and MSH2 can be verified using quantitative PCR. Assays using this method are simple to design and easy to perform, making them ideal for confirmatory testing.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18556772      PMCID: PMC2438205          DOI: 10.2353/jmoldx.2008.080021

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  20 in total

1.  A new mathematical model for relative quantification in real-time RT-PCR.

Authors:  M W Pfaffl
Journal:  Nucleic Acids Res       Date:  2001-05-01       Impact factor: 16.971

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 3.  The detection of large deletions or duplications in genomic DNA.

Authors:  J A L Armour; D E Barton; D J Cockburn; G R Taylor
Journal:  Hum Mutat       Date:  2002-11       Impact factor: 4.878

4.  Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.

Authors:  Jan P Schouten; Cathal J McElgunn; Raymond Waaijer; Danny Zwijnenburg; Filip Diepvens; Gerard Pals
Journal:  Nucleic Acids Res       Date:  2002-06-15       Impact factor: 16.971

Review 5.  MLPA and MAPH: new techniques for detection of gene deletions.

Authors:  Loryn N Sellner; Graham R Taylor
Journal:  Hum Mutat       Date:  2004-05       Impact factor: 4.878

6.  Rapid detection of CFTR gene rearrangements impacts on genetic counselling in cystic fibrosis.

Authors:  F Niel; J Martin; F Dastot-Le Moal; B Costes; B Boissier; V Delattre; M Goossens; E Girodon
Journal:  J Med Genet       Date:  2004-11       Impact factor: 6.318

7.  MSH2 genomic deletions are a frequent cause of HNPCC.

Authors:  J Wijnen; H van der Klift; H Vasen; P M Khan; F Menko; C Tops; H Meijers Heijboer; D Lindhout; P Møller; R Fodde
Journal:  Nat Genet       Date:  1998-12       Impact factor: 38.330

8.  Identification and characterization of genomic rearrangements of MSH2 and MLH1 in Lynch syndrome (HNPCC) by novel techniques.

Authors:  Hidewaki Nakagawa; Heather Hampel; Albert de la Chapelle
Journal:  Hum Mutat       Date:  2003-09       Impact factor: 4.878

9.  Gross rearrangements in the MECP2 gene in three patients with Rett syndrome: implications for routine diagnosis of Rett syndrome.

Authors:  E Schollen; E Smeets; E Deflem; J P Fryns; G Matthijs
Journal:  Hum Mutat       Date:  2003-08       Impact factor: 4.878

10.  Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene.

Authors:  Anja Wagner; Alicia Barrows; Juul Th Wijnen; Heleen van der Klift; Patrick F Franken; Paul Verkuijlen; Hidewaki Nakagawa; Marjan Geugien; Shantie Jaghmohan-Changur; Cor Breukel; Hanne Meijers-Heijboer; Hans Morreau; Marjo van Puijenbroek; John Burn; Stephany Coronel; Yulia Kinarski; Ross Okimoto; Patrice Watson; Jane F Lynch; Albert de la Chapelle; Henry T Lynch; Riccardo Fodde
Journal:  Am J Hum Genet       Date:  2003-03-25       Impact factor: 11.025

View more
  3 in total

1.  LightCycler technology in molecular diagnostics.

Authors:  Elaine Lyon; Carl T Wittwer
Journal:  J Mol Diagn       Date:  2009-02-05       Impact factor: 5.568

2.  Evaluation of microsatellite instability in women with epithelial ovarian cancer.

Authors:  Leonardo Pandolfi Caliman; Rubens Lene Carvalho Tavares; Josiane Barbosa Piedade; Ana Carolina Silvano Couto DE Assis; Karen DE Jesus Dias DA Cunha; Letícia DA Conceição Braga; Luciana Maria Silva; Agnaldo Lopes DA Silva Filho
Journal:  Oncol Lett       Date:  2012-06-27       Impact factor: 2.967

3.  Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.

Authors:  Xavier Gabaldó Barrios; Mª Desamparados Sarabia Meseguer; Miguel Marín Vera; Ana Isabel Sánchez Bermúdez; José Antonio Macías Cerrolaza; Pilar Sánchez Henarejos; Marta Zafra Poves; Mª Rosario García Hernández; Encarna Cuevas Tortosa; Ángeles Aliaga Baño; Verónica Castillo Guardiola; Pedro Martínez Hernández; Isabel Tovar Zapata; Enrique Martínez Barba; Francisco Ayala de la Peña; José Luis Alonso Romero; José Antonio Noguera Velasco; Francisco Ruiz Espejo
Journal:  Fam Cancer       Date:  2017-10       Impact factor: 2.375

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.